← Leaderboards
Dean Yoshimasa Maeda
Syntrix Biosystems, Inc.
$6,126,552
Attributed
$9,748,885
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–20$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$9,748,885 · 3
By mechanism
R44$9,585,556 · 2
R43$163,329 · 1
Top collaborators
- Stuart J Kahn3 shared
- John A Zebala3 shared
Most similar at Syntrix Biosystems, Inc.
Same institution · by research overlap
- John A Zebala$18,699,047
- Aaron D Schuler$1,538,086
Others in their field
Top investigators on “Neutrophil”
- Charles Nicholas Serhan · Brigham And Women'S Hospital$23,875,763
- Hongbo R Luo · Children'S Hospital Boston$23,323,359
- Tanya N. Mayadas · Brigham And Women'S Hospital$21,795,639
- Victor Nizet · University Of California, San Diego$21,031,691
- J. Edwin Blalock · University Of Alabama At Birmingham$19,196,735
- Robert Fairchild · Cleveland Clinic Lerner Com-Cwru$18,658,323
Research focus
NeutrophilIl8rb GeneOralAffectEvaluationExhibitsPre-ClinicalResearch Clinical TestingLeadSmall MoleculeSmall Business Innovation Research GrantSiteIl8ra GeneBronchopulmonary DysplasiaFundingPharmaceutical PreparationsChemotaxisChemokineDoseSafetyInhibitor/AntagonistInflammatoryInjuryAnti-Inflammatory Agents
Grant awards (11)
HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients$1,575,472
R44 · FY2020 · HL
HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients$1,424,426
R44 · FY2019 · HL
HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients$398,444
R44 · FY2018 · HL
Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD$1,887,898
R44 · FY2014 · HL · contact PI
Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD$1,147,002
R44 · FY2012 · HL · contact PI
Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD$811,424
R44 · FY2011 · HL · contact PI
Bronchopulmonary Dysplasia Drug Therapy$218,812
R44 · FY2010 · HL · contact PI
Bronchopulmonary Dysplasia Drug Therapy$705,130
R44 · FY2007 · HL · contact PI
Bronchopulmonary Dysplasia Drug Therapy$705,130
R44 · FY2006 · HL · contact PI
Bronchopulmonary Dysplasia Drug Therapy$711,818
R44 · FY2005 · HL
Bronchopulmonary Dysplasia Drug Therapy$163,329
R43 · FY2003 · HL